Name: KNSA Income Statement - Kiniksa Pharmaceuticals International Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

KNSA - Kiniksa Pharmaceuticals International, PLC

USD | NASDAQ | Healthcare

KNSA Income Statement - Kiniksa Pharmaceuticals International Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q4 FY 18	Q3 FY 18	Q2 FY 18	Q1 FY 18	Q3 FY 17	Q2 FY 17
Revenues
Revenues	214.3	202.1	180.9	156.8	137.8	122.5	112.2	108.6	79.9	83.4	67.0	71.5	48.3	61.9	99.1	27.0

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
Revenues
Revenues	754.0	677.6	423.2	270.3	220.2	38.5	-	-	-	-
Cost of Revenue	80.6	77.7	60.9	33.4	22.9	9.1	-	-	-	-
Gross Profit	673.4	599.9	362.3	236.9	197.3	29.4	-	-	-	-
Operating Expenses
Research & Development	105.0	96.9	111.6	76.1	65.5	99.3	112.0	135.0	86.6	56.4
Selling General & Administrative	213.9	196.3	168.0
Operating Income
Operating Income	93.2	77.2	(45.6)	(25.2)	9.8	(156.6)	(157.4)	(170.0)	(108.2)	(65.4)
Non-Operating
Interest Income	-	11.6	9.0	8.2	1.2	0.1	1.1	6.0	4.7	0.5
Interest Expense	-	-	-	-
Tax & Net
Income Tax Expense	32.9	29.9	7.0	(30.7)	(172.3)	1.4	5.2	(2.0)	(0.2)	0.0
Net Income From Continuing Ops	73.1	59.0	(43.2)
Per Share
EPS Basic	0.95	0.80	(0.60)	0.20	2.64	(2.30)	(2.61)	(2.99)	-	-
EPS Diluted	0.89	0.75	(0.60)	0.20
Supplementary Data
EBITDA	94.9	78.8	(43.9)	(22.9)	12.2	(154.3)	(155.0)	(167.9)	(107.9)	(65.4)
EBIT	93.2	77.2	(45.6)	(25.2)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Expenses
Research & Development	27.5	34.6	24.2	18.8	19.3	35.2	26.1	24.0	26.3	20.1	17.1	23.8	15.2	14.4	16.5	13.8	20.8	27.4	19.2	23.9	28.7	37.4	31.4	22.3	20.9	22.9	22.0	30.8	59.3	36.1	20.6	17.2	12.6	14.0	9.3
Selling General & Administrative	61.2	56.8	49.1	46.9	43.5	40.5	46.4	42.4	38.7	36.7	34.5	29.2	29.0	27.2	24.7	23.8
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation & Amortization	0.5	1.2	0.0	0.0	0.3	1.0	0.1	0.1	0.5	1.2	0.3	0.3	0.6	1.2	0.2	0.4
Amortization of Intangibles	0.3	-	0.3	0.3	0.3	-	0.3	0.3	-	-	-	-	-	-	-	-	-
Other Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Operating Income
Operating Income	29.3	19.8	24.0	20.2	13.3	(19.3)	(9.7)	(0.1)	(16.5)	0.1	(10.9)	(3.2)	(11.2)	6.0	46.4	(19.4)	(23.3)	(36.1)	(30.7)	(40.6)	(49.3)	(52.9)	(43.2)	(31.9)	(29.4)	(32.6)	(30.4)	(39.3)	(67.6)	(44.1)	(26.2)	(21.5)	(16.3)	(16.2)	(11.4)

Tax & Net
Income Tax Expense	10.1	9.1	8.7	5.0	7.0	(8.1)	5.5	6.2	3.4	(22.8)	5.4	(16.2)	2.9	2.4	(177.4)	0.7	1.9	0.3	(0.1)	1.0	0.2	0.8	0.7	5.9	(2.2)	0.3	(2.0)	(0.4)	(0.0)	0.2	(0.1)	(0.2)	(0.1)	(0.1)	(0.0)
Net Income From Continuing Ops	22.6	14.2	18.4	17.8	8.5	(8.9)	(12.7)	(3.9)	(17.7)	25.2	(13.9)	15.0	(12.3)	4.5	224.1	(20.0)	(25.2)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	22.6	14.2	18.4	17.8	8.5	(8.9)	(12.7)	(3.9)	(17.7)	25.2	(13.9)	15.0	(12.3)	4.5	224.1	(20.0)	(25.2)
Net Income Attributable To Parent	22.6	14.2	18.4	17.8	8.5	(8.9)	(12.7)	(3.9)	(17.7)	25.2	(13.9)	15.0	(12.3)	4.5	224.1	(20.0)
Less: Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: Preferred Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income To Common Shareholders	22.6	14.2	18.4	17.8	8.5	(8.9)	(12.7)	(3.9)	(17.7)	25.2	(13.9)	15.0	(12.3)	4.5	224.1

Per Share
EPS Basic	0.30	-	0.25	0.24	0.12	-	(0.18)	(0.06)	(0.25)	-	(0.20)	0.21	(0.18)	-	3.23	(0.29)	(0.36)	-	(0.44)	(0.61)	(0.72)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Diluted	0.27	-	0.23	0.23	0.11	-	(0.18)	(0.06)	(0.25)	-	(0.20)	0.21	(0.18)	-	3.18	(0.29)	(0.36)	-
Shares Basic	76.5	-	74.7	73.4	72.6	-	71.7	71.0	70.6	-	70.2	69.9	69.8	-	69.4	69.3	69.1	-
Shares Diluted	82.4	-	80.0	77.9	76.1	-	71.7	71.0	70.6	-	70.2	71.6	69.8	-	70.6	69.3	69.1	-

Supplementary Data
EBITDA	29.7	20.9	24.0	20.2	13.6	(18.3)	(9.6)	0.0	(16.1)	1.2	(10.6)	(2.9)	(10.6)	7.3	46.6	(19.0)	(22.7)	(34.9)	(30.3)	(40.1)	(49.0)	(52.3)	(42.6)	(31.3)	(28.8)	(32.0)	(29.9)	(38.8)	(67.2)	(43.9)	(26.1)	(21.5)	(16.3)	(16.2)	(11.4)
EBIT	29.3	19.8	24.0	20.2	13.3	(19.3)	(9.7)	(0.1)	(16.5)	0.1	(10.9)	(3.2)	(11.2)	6.0	46.4	(19.4)	(23.3)	(36.1)	(30.7)